EB-PSMA-617 | CAS#2250333-97-0 | iamaging agent

EB-PSMA-617
new

featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 125682

CAS#: 2250333-97-0

Description: EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.

Chemical Structure

EB-PSMA-617

CAS# 2250333-97-0

Instruction

Theoretical Analysis

MedKoo Cat#: 125682
Name: EB-PSMA-617
CAS#: 2250333-97-0
Chemical Formula: C87H110N16O28S3
Exact Mass: 1,922.68
Molecular Weight: 1,924.100
Elemental Analysis: C, 54.31; H, 5.76; N, 11.65; O, 23.28; S, 5.00

Price and Availability

Size	Price	Availability
5mg	USD 1650	2 Weeks
10mg	USD 2950	2 Weeks
100mg	USD 6950	2 Weeks
500mg	USD 12950	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: EB-PSMA-617; EB-PSMA 617; EB PSMA-617; EB PSMA 617; EB-PSMA617;

IUPAC/Chemical Name: (((1S)-5-((2S)-2-(4-((2-((1-(2-(((S)-6-((4'-((8-amino-1-hydroxy-5,7-disulfonaphthalen-2-yl)diazenyl)-3,3'-dimethyl-[1,1'-biphenyl]-4-yl)amino)-6-oxo-5-(2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetamido)hexyl)amino)-2-oxoethyl)-2,5-dioxopyrrolidin-3-yl)thio)acetamido)methyl)cyclohexane-1-carboxamido)-3-(naphthalen-2-yl)propanamido)-1-carboxypentyl)carbamoyl)-L-glutamic acid

InChi Key: ZZOPIXCOCDFJQS-QWPCFAHTSA-N

InChi Code: InChI=1S/C87H110N16O28S3/c1-50-37-57(58-20-23-61(51(2)38-58)97-98-62-24-21-59-68(133(126,127)128)42-69(134(129,130)131)79(88)78(59)80(62)116)19-22-60(50)93-83(119)63(92-71(105)44-99-29-31-100(46-75(110)111)33-35-102(48-77(114)115)36-34-101(32-30-99)47-76(112)113)11-5-7-27-89-70(104)45-103-73(107)41-67(84(103)120)132-49-72(106)91-43-52-13-17-55(18-14-52)81(117)94-66(40-53-15-16-54-9-3-4-10-56(54)39-53)82(118)90-28-8-6-12-64(85(121)122)95-87(125)96-65(86(123)124)25-26-74(108)109/h3-4,9-10,15-16,19-24,37-39,42,52,55,63-67,116H,5-8,11-14,17-18,25-36,40-41,43-49,88H2,1-2H3,(H,89,104)(H,90,118)(H,91,106)(H,92,105)(H,93,119)(H,94,117)(H,108,109)(H,110,111)(H,112,113)(H,114,115)(H,121,122)(H,123,124)(H2,95,96,125)(H,126,127,128)(H,129,130,131)/t52-,55-,63-,64?,65?,66-,67?/m0/s1

SMILES Code: O=C(CN1CCN(CCN(CCN(CC1)CC(O)=O)CC(O)=O)CC(O)=O)N[C@H](C(NC2=CC=C(C3=CC=C(N=NC4=C(O)C(C(N)=C(S(=O)(O)=O)C=C5S(=O)(O)=O)=C5C=C4)C(C)=C3)C=C2C)=O)CCCCNC(CN6C(CC(SCC(NC[C@@H]7CCC(C(N[C@H](C(NCCCC[C@H](NC(N[C@@H](CCC(O)=O)C(O)=O)=O)C(O)=O)=O)CC8=CC9=C(C=CC=C9)C=C8)=O)CC7)=O)C6=O)=O)=O

Appearance: To be determined

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 1,924.10 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Zang J, Fan X, Wang H, Liu Q, Wang J, Li H, Li F, Jacobson O, Niu G, Zhu Z,
Chen X. First-in-human study of ¹⁷⁷Lu-EB-PSMA-617 in patients with
metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging.
2019 Jan;46(1):148-158. doi: 10.1007/s00259-018-4096-y. Epub 2018 Aug 8. PMID:
30090965; PMCID: PMC6250576.

2: Lu Q, Long Y, Gai Y, Liu Q, Jiang D, Lan X. [¹⁷⁷Lu]Lu-PSMA-617
theranostic probe for hepatocellular carcinoma imaging and therapy. Eur J Nucl
Med Mol Imaging. 2023 Jul;50(8):2342-2352. doi: 10.1007/s00259-023-06155-x. Epub
2023 Mar 6. PMID: 36877233.

3: Zang J, Liu Q, Sui H, Wang R, Jacobson O, Fan X, Zhu Z, Chen X.
¹⁷⁷Lu-EB-PSMA Radioligand Therapy with Escalating Doses in Patients
with Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2020
Dec;61(12):1772-1778. doi: 10.2967/jnumed.120.242263. Epub 2020 May 1. PMID:
32358086; PMCID: PMC9364902.

4: Wang Z, Tian R, Niu G, Ma Y, Lang L, Szajek LP, Kiesewetter DO, Jacobson O,
Chen X. Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand
Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors. Bioconjug
Chem. 2018 Sep 19;29(9):3213-3221. doi: 10.1021/acs.bioconjchem.8b00556. Epub
2018 Aug 22. PMID: 30105912.

5: Wen X, Xu P, Zeng X, Liu J, Du C, Zeng X, Cheng X, Wang X, Liang Y, Zhao T,
Yang H, Li H, Meng L, Fang J, Liu H, Zhou Z, Zhang J, Zhang X, Guo Z, Chen X.
Development of [¹⁷⁷Lu]Lu-LNC1003 for radioligand therapy of prostate
cancer with a moderate level of PSMA expression. Eur J Nucl Med Mol Imaging.
2023 Jul;50(9):2846-2860. doi: 10.1007/s00259-023-06229-w. Epub 2023 Apr 25.
PMID: 37097443.

6: Ghodsirad MA, Pirayesh E, Akbarian R, Javanmard B, Kaghazchi F, Tavakoli M,
Fattahi K. Diagnostic Utility of Lutetium-177 (Lu 177) Prostate-Specific
Membrane Antigen (PSMA) Scintigraphy In Prostate Cancer Patients With PSA Rise
And Negative Conventional Imaging. Urol J. 2020 Jun 23;17(4):374-378. doi:
10.22037/uj.v0i0.5451. PMID: 32281092.

Your view history

EB-PSMA-617 new featured